Tempus, AstraZeneca, and Pathos Partner to Build Oncology Foundation Model Using Multimodal Data
Tempus has announced new multi-year agreements with AstraZeneca and Pathos AI to co-develop what is described as the largest multimodal foundation model in oncology.
The model will be trained on Tempus’ de-identified oncology datasets and is intended to support research across biological insight generation, target discovery, and therapeutic development. All three partners will have access to the resulting model for use in their respective R&D efforts. The deal includes $200 million in combined fees for data licensing and model development.
Topics: AI & Digital